Pharmacological Activities of Alisma orientale against Nonalcoholic Fatty Liver Disease and Metabolic Syndrome: Literature Review

Abstract EN

Nonalcoholic fatty liver disease (NAFLD) is a rapidly emerging hepatic manifestation of metabolic syndrome.

However, its unrevealed mechanism and complicated comorbidities have led to no specific medication, except for weight loss and lifestyle modification.

Alisma orientale (Sam.) Juzep (A.

orientale, Alismataceae) has been increasingly reported on therapeutic effects of A.

orientale against NAFLD and metabolic syndrome such as insulin resistance, hyperlipidemia, and obesity.

Therefore, this study aimed to review the preclinical efficacy of A.

orientale and its chemical constituents including Alisol A 24-acetate, Alisol B 23-acetate, Alisol F, and Alismol against NAFLD and metabolic syndrome.

A.

orientale prevented hepatic triglyceride accumulation through suppressing de novo lipogenesis and increasing lipid export.

In addition, it controlled oxidative stress markers, lipoapoptosis, liver injury panels, and inflammatory and fibrotic mediators, eventually influencing steatohepatitis and liver fibrosis.

Moreover, it exhibited pharmacological activities against hyperlipidemia, obesity, and hyperglycemia as well as appetite.

These biological actions of A.

orientale might contribute to adiponectin activation or a role as a farnesoid X receptor agonist.

In particular, Alisol A 24-acetate and Alisol B 23-acetate could be expected as main compounds.

Taken together, A.

orientale might be an effective candidate agent for the treatment of NAFLD and its comorbidities, although further assessment of its standardization, safety test, and clinical trials is consistently required.